1. ROADS phase III: GammaTile improves surgical bed control after brain metastasis resection
In 204 patients, intraoperative cesium-131 GammaTile reduced 12-month surgical bed recurrence to 1.3% versus 15.4% with postoperative stereotactic RT. Radiation necrosis rates were similar, although longer follow-up is needed to establish late safety and survival benefits.
2. ESTRO publishes new radiotherapy guidance for Merkel cell carcinoma
The new ESTRO guideline recommends 60 Gy in 30 fractions for definitive treatment and at least 50 Gy in 25 fractions postoperatively. It also addresses target margins, timely treatment, and risk-adapted nodal irradiation, providing practical guidance for this rare malignancy.
3. Early nutritional supplementation reduces weight loss during nasopharyngeal chemoradiotherapy
In a randomized trial involving 216 evaluable patients, starting nutritional supplementation at the beginning of chemoradiotherapy reduced >5% weight loss from 80.7% to 65.4%. Grade ≥3 oral mucositis was also less frequent (14.0% vs 26.6%).
4. HARVEST phase III: three-week regional nodal irradiation shows comparable acute toxicity
In 801 patients with node-positive breast cancer, 40.05 Gy in 15 fractions produced similar overall acute toxicity to 50 Gy in 25 fractions, including comprehensive internal mammary irradiation. Moderate dermatitis was less frequent with hypofractionation, while the primary locoregional recurrence endpoint remains pending.
5. SRAM: pelvic prostate SBRT worsens patient-reported bowel function despite similar physician-graded toxicity
In 121 evaluable high-risk prostate cancer patients, once-weekly pelvic SBRT produced similar grade ≥2 gastrointestinal toxicity to conventional IMRT (16.7% vs 13.1%). However, one-year patient-reported bowel scores were significantly worse (82.5 vs 90.1), highlighting a toxicity signal not fully captured by physician grading.
That's the week. See you next Sunday.